In this way, they demonstrated that acting on glutamatergic signalling, and specifically potentiating AMPAR, could prevent tau-mediated toxic synaptic effects, therefore providing a potential pathway for new and alternative treatments of AD and other tauopathies. Here, MAPT is linked to Alzheimer disease.